As New Jersey’s only NCI-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health, provides patients access to the most advanced treatment options including complex surgical procedures, sophisticated radiation therapy techniques, innovative clinical trials, immunotherapy, and precision medicine.
|
|
|
Research Leader from the National Cancer Institute Appointed to Co-direct the Cancer Immunology and Metabolism Center of Excellence |
|
|
|
Immunology and immunotherapy expert Christian Hinrichs, MD, recently began his new role at Rutgers Cancer Institute as chief of the Section of Cancer Immunotherapy and co-director of the Cancer Immunology and Metabolism Center of Excellence along with Eileen White, PhD, deputy director and chief scientific officer at Rutgers Cancer Institute. In his new role, Dr. Hinrichs, who joins us from the National Cancer Institute, will work with Dr. White to develop a center that integrates ground-breaking research in cancer metabolism and cutting-edge immunotherapy to improve cancer treatment for patients. Learn more
|
|
New Non-Surgical Therapy for Urothelial Cancer Available at Rutgers Cancer Institute |
|
|
|
Upper tract urothelial cancer (UTUC) is a subset of urothelial cancer that is found in the renal pelvis or the ureter, part of the genitourinary tract. Surgery has remained the mainstay of treatment for this type of cancer, until last year, when the U.S. Food and Drug Administration approved mitomycin gel as the first non-surgical therapy option to treat this type of cancer. Rutgers Cancer Institute of New Jersey recently began offering this new therapy for UTUC patients. Saum Ghodoussipour, MD, urologic oncologist and director of the Bladder and Urothelial Cancer Program at Rutgers Cancer Institute and assistant professor of surgery at Rutgers Robert Wood Johnson Medical School, shares more about this new sophisticated treatment. Read more
|
|
New Gynecologic Oncology Leader Named at Rutgers Cancer Institute |
|
|
|
Rutgers Cancer Institute of New Jersey has named James K. Aikins, Jr., MD, FACOG, FACS as its new chief and leader of the Gynecologic Oncology Program, which offers advanced treatment options including minimally invasive surgical techniques, clinical trials, precision medicine, and immunotherapy. Dr. Aikins also serves as chief of gynecologic oncology services at Robert Wood Johnson University Hospital, an RWJBarnabas Health facility and New Jersey’s largest academic medical center, and Program Director for the Gynecologic Oncology Fellowship Program at Rutgers Robert Wood Johnson Medical School. Learn more
|
|
Exploring Tamoxifen Resistance Markers in Breast Cancer Treatment |
|
|
|
Nearly 70 percent of all cases of breast cancer are estrogen receptor (ER) positive. In a recent study, researchers from Rutgers University explored the therapeutic response to tamoxifen, a drug that blocks the activity of estrogen in the breast, by using a computational framework to predict treatment resistance based on behavior of molecular pathways. Antonina Mitrofanova, PhD, researcher at Rutgers Cancer Institute of New Jersey and assistant professor at the Rutgers School of Health Professions, is the senior and corresponding author of the work. The findings have been published online in the November 2020 issue of EBioMedicine. Learn more
|
|
|
|
Rutgers Cancer Institute of New Jersey in partnership with RWJBarnabas Health, helps individuals fight cancer through research and collaborations with teams locally and across the globe. Howard S. Hochster, MD, FACP, associate director for clinical research at Rutgers Cancer Institute; director of oncology research at RWJBarnabas Health; and distinguished professor of medicine, Rutgers Robert Wood Johnson Medical School, shares more about how our every-day collaborative efforts are impacting the cancer fight. Learn more
|
|
|
|
|
|
|
